SE9904176D0 - New use - Google Patents

New use

Info

Publication number
SE9904176D0
SE9904176D0 SE9904176A SE9904176A SE9904176D0 SE 9904176 D0 SE9904176 D0 SE 9904176D0 SE 9904176 A SE9904176 A SE 9904176A SE 9904176 A SE9904176 A SE 9904176A SE 9904176 D0 SE9904176 D0 SE 9904176D0
Authority
SE
Sweden
Prior art keywords
new use
disorders
prophylaxis
enantiomers
therapy
Prior art date
Application number
SE9904176A
Other languages
English (en)
Swedish (sv)
Inventor
Michael Balestra
George Mullen
Eifion Phillips
Richard Schmiesing
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9904176A priority Critical patent/SE9904176D0/xx
Publication of SE9904176D0 publication Critical patent/SE9904176D0/xx
Priority to ARP000105840A priority patent/AR031680A1/es
Priority to CN008184216A priority patent/CN1217943C/zh
Priority to EEP200200251A priority patent/EE200200251A/xx
Priority to IL14937400A priority patent/IL149374A0/xx
Priority to PCT/SE2000/002262 priority patent/WO2001036417A1/en
Priority to DE60020994T priority patent/DE60020994T2/de
Priority to AU19073/01A priority patent/AU784400B2/en
Priority to PL00355867A priority patent/PL355867A1/xx
Priority to US10/130,635 priority patent/US6683090B1/en
Priority to HU0204245A priority patent/HUP0204245A3/hu
Priority to JP2001538906A priority patent/JP2003514818A/ja
Priority to SK677-2002A priority patent/SK6772002A3/sk
Priority to NZ518571A priority patent/NZ518571A/en
Priority to MXPA02004911A priority patent/MXPA02004911A/es
Priority to DK00981994T priority patent/DK1233964T3/da
Priority to HK02109290.6A priority patent/HK1047743B/en
Priority to BR0015624-8A priority patent/BR0015624A/pt
Priority to CA002389604A priority patent/CA2389604A1/en
Priority to SI200030716T priority patent/SI1233964T1/xx
Priority to CZ20021692A priority patent/CZ20021692A3/cs
Priority to KR1020027006257A priority patent/KR20020058014A/ko
Priority to PT00981994T priority patent/PT1233964E/pt
Priority to UA2002065003A priority patent/UA74172C2/uk
Priority to ES00981994T priority patent/ES2242653T3/es
Priority to EP00981994A priority patent/EP1233964B1/en
Priority to AT00981994T priority patent/ATE298337T1/de
Priority to CO00087729A priority patent/CO5261607A1/es
Priority to ZA200203316A priority patent/ZA200203316B/xx
Priority to BG106680A priority patent/BG106680A/bg
Priority to NO20022289A priority patent/NO20022289L/no
Priority to IS6385A priority patent/IS6385A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE9904176A 1999-11-18 1999-11-18 New use SE9904176D0 (sv)

Priority Applications (32)

Application Number Priority Date Filing Date Title
SE9904176A SE9904176D0 (sv) 1999-11-18 1999-11-18 New use
ARP000105840A AR031680A1 (es) 1999-11-18 2000-11-06 Utilizacion de acrilamidas de quinuclidina para la preparacion de medicamentos, compuestos y composicion farmaceutica
AT00981994T ATE298337T1 (de) 1999-11-18 2000-11-16 Neue verwendung sowie neue n-azabicycloamid- verbindungen
MXPA02004911A MXPA02004911A (es) 1999-11-18 2000-11-16 Nuevo uso y nuevos derivados de n-azabiciclo-amida.
BR0015624-8A BR0015624A (pt) 1999-11-18 2000-11-16 Uso de um composto, composto, composição farmacêutica, e, método de tratamento ou profilaxia de doenças ou condições humanas
IL14937400A IL149374A0 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
PCT/SE2000/002262 WO2001036417A1 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
DE60020994T DE60020994T2 (de) 1999-11-18 2000-11-16 Neue verwendung sowie neue n-azabicycloamid-verbindungen
AU19073/01A AU784400B2 (en) 1999-11-18 2000-11-16 New use and novel N-azabicyclo-amide derivatives
PL00355867A PL355867A1 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
US10/130,635 US6683090B1 (en) 1999-11-18 2000-11-16 N-azabicyclo-amide derivatives
HU0204245A HUP0204245A3 (en) 1999-11-18 2000-11-16 Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
JP2001538906A JP2003514818A (ja) 1999-11-18 2000-11-16 新規使用および新規ｎ−アザビシクロ−アミド誘導体
SK677-2002A SK6772002A3 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
NZ518571A NZ518571A (en) 1999-11-18 2000-11-16 New use and novel N-azabicyclo-amide derivatives
CN008184216A CN1217943C (zh) 1999-11-18 2000-11-16 新的用途和新的n－氮杂双环－酰胺衍生物
DK00981994T DK1233964T3 (da) 1999-11-18 2000-11-16 Ny anvendelse og hidtil ukendte N-azabicycloamidderivater
HK02109290.6A HK1047743B (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
EEP200200251A EE200200251A (et) 1999-11-18 2000-11-16 Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
CA002389604A CA2389604A1 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
SI200030716T SI1233964T1 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
CZ20021692A CZ20021692A3 (cs) 1999-11-18 2000-11-16 Nové N-azabicykloamidové deriváty a jejich pouľití
KR1020027006257A KR20020058014A (ko) 1999-11-18 2000-11-16 신규 용도 및 신규 ｎ-아자비시클로-아미드 유도체
PT00981994T PT1233964E (pt) 1999-11-18 2000-11-16 Nova utilizacao e novos derivados de n-azabiciclo-amida
UA2002065003A UA74172C2 (uk) 1999-11-18 2000-11-16 ЗАСТОСУВАННЯ ПОХІДНИХ N-АЗАБІЦИКЛОАМІДУ ДЛЯ ЛІКУВАННЯ ЧИ ПРОФІЛАКТИКИ ПСИХОТИЧНИХ РОЗЛАДІВ, А ТАКОЖ СТАНІВ, КОЛИ КОРИСНОЮ Є СТИМУЛЯЦІЯ НІКОТИНОВОГО РЕЦЕПТОРА <font face="Symbol">a7</font>
ES00981994T ES2242653T3 (es) 1999-11-18 2000-11-16 Nuevo uso y nuevos derivados de n-azabiciclo-amida.
EP00981994A EP1233964B1 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
CO00087729A CO5261607A1 (es) 1999-11-18 2000-11-17 Nuevo uso
ZA200203316A ZA200203316B (en) 1999-11-18 2002-04-25 New use and novel n-azabicyclo-amide derivatives.
BG106680A BG106680A (bg) 1999-11-18 2002-05-09 Ново приложение и нови производни на n-азабициклоамид
NO20022289A NO20022289L (no) 1999-11-18 2002-05-14 Ny anvendelse og nye N-azabisykloamidderivater
IS6385A IS6385A (is) 1999-11-18 2002-05-15 Ný notkun og nýjar N-asabísýkló-amíð afleiður

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904176A SE9904176D0 (sv) 1999-11-18 1999-11-18 New use

Publications (1)

Publication Number Publication Date
SE9904176D0 true SE9904176D0 (sv) 1999-11-18

Family

ID=20417766

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904176A SE9904176D0 (sv) 1999-11-18 1999-11-18 New use

Country Status (30)

Country Link
US (1) US6683090B1 (OSRAM)
EP (1) EP1233964B1 (OSRAM)
JP (1) JP2003514818A (OSRAM)
KR (1) KR20020058014A (OSRAM)
CN (1) CN1217943C (OSRAM)
AR (1) AR031680A1 (OSRAM)
AT (1) ATE298337T1 (OSRAM)
AU (1) AU784400B2 (OSRAM)
BG (1) BG106680A (OSRAM)
BR (1) BR0015624A (OSRAM)
CA (1) CA2389604A1 (OSRAM)
CO (1) CO5261607A1 (OSRAM)
CZ (1) CZ20021692A3 (OSRAM)
DE (1) DE60020994T2 (OSRAM)
DK (1) DK1233964T3 (OSRAM)
EE (1) EE200200251A (OSRAM)
ES (1) ES2242653T3 (OSRAM)
HU (1) HUP0204245A3 (OSRAM)
IL (1) IL149374A0 (OSRAM)
IS (1) IS6385A (OSRAM)
MX (1) MXPA02004911A (OSRAM)
NO (1) NO20022289L (OSRAM)
NZ (1) NZ518571A (OSRAM)
PL (1) PL355867A1 (OSRAM)
PT (1) PT1233964E (OSRAM)
SE (1) SE9904176D0 (OSRAM)
SK (1) SK6772002A3 (OSRAM)
UA (1) UA74172C2 (OSRAM)
WO (1) WO2001036417A1 (OSRAM)
ZA (1) ZA200203316B (OSRAM)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
WO2002016358A2 (en) * 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002016357A2 (en) * 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002016356A2 (en) * 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
EP1311505A2 (en) * 2000-08-21 2003-05-21 PHARMACIA &amp; UPJOHN COMPANY Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
WO2002017358A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036041A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
DE60215172T2 (de) * 2001-07-06 2007-08-30 Neurosearch A/S Neue verbindungen, deren herstellung und verwendung
WO2003018585A1 (en) * 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
KR100614900B1 (ko) * 2001-10-02 2006-08-25 파마시아 앤드 업존 캄파니 엘엘씨 질병의 치료를 위한 아자비시클릭-치환된 융합-헤테로아릴화합물
US20040259909A1 (en) * 2001-10-16 2004-12-23 Mccarthy Dennis Treatment of fibromyalgia syndrome
BR0213760A (pt) * 2001-10-26 2004-10-19 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
CA2466375A1 (en) 2001-11-08 2003-05-15 Pharmacia & Upjohn Company Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
EP1442037A1 (en) 2001-11-09 2004-08-04 PHARMACIA &amp; UPJOHN COMPANY Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
BR0214929A (pt) 2001-12-14 2006-05-30 Targacept Inc métodos e composições para o tratamento de distúrbios do sistema nervoso central
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
AU2003210730A1 (en) 2002-02-15 2003-09-09 Pharmacia And Upjohn Company Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
US6858613B2 (en) 2002-02-19 2005-02-22 Pfizer Inc. Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
CA2476624A1 (en) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
MXPA04011858A (es) 2002-05-30 2005-03-31 Neurosearch As Quinuclidinas sustituidas en la posicion 3 y su uso.
EP1542999A1 (en) 2002-08-01 2005-06-22 Pharmacia & Upjohn Company LLC 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
CA2495248A1 (en) 2002-08-30 2004-03-11 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
KR101129933B1 (ko) 2002-09-25 2012-03-23 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸 및 벤조이소티아졸 및 그의 제조 및용도
WO2004052348A2 (en) * 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
US7402592B2 (en) 2003-10-15 2008-07-22 Targacept, Inc. Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders
JP4995075B2 (ja) 2004-03-25 2012-08-08 メモリー・ファーマシューティカルズ・コーポレイション インダゾール、ベンゾチアゾール、ベンゾイソチアゾール、ベンズイソキサゾール、ならびにそれらの調製および使用
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
ATE482959T1 (de) 2005-08-22 2010-10-15 Targacept Inc Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
JP5109132B2 (ja) * 2005-09-28 2012-12-26 国立大学法人 熊本大学 注意欠陥・多動性障害の治療薬
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
WO2008008884A2 (en) * 2006-07-12 2008-01-17 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009046025A1 (en) 2007-10-01 2009-04-09 Comentis, Inc. Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease
US20110059947A1 (en) 2008-02-13 2011-03-10 Targacept, Inc. Alpha 7 nicotinic agonists and antipsychotics
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
ES2570657T3 (es) 2010-05-17 2016-05-19 Forum Pharmaceuticals Inc Una forma cristalina de hidrocloruro de (R)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidrato
FR2974365B1 (fr) * 2011-04-20 2017-08-25 Centre Nat De La Rech Scient (C N R S) 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques
WO2012177856A2 (en) * 2011-06-21 2012-12-27 Adispell, Inc. Cognition modification
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
EA029430B1 (ru) 2013-06-21 2018-03-30 Такеда Фармасьютикл Компани Лимитед Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
AR101131A1 (es) 2014-07-11 2016-11-23 Comentis Inc QUINUCLIDINAS PARA LA MODULACIÓN DE ACTIVIDAD DE a7
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1255467B (it) * 1992-07-29 1995-11-02 Dompe Farmaceutici Spa Ammidi acriliche farmacologicamente attive
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
TR199700625T1 (xx) * 1995-01-10 1998-02-21 Smithkline Beecham S.P.A. Osteoporoz (kemik erimesi) tedavisinde yararl� olan indol t�revleri.

Also Published As

Publication number Publication date
UA74172C2 (uk) 2005-11-15
EP1233964B1 (en) 2005-06-22
CN1217943C (zh) 2005-09-07
JP2003514818A (ja) 2003-04-22
HK1047743A1 (en) 2003-03-07
WO2001036417A1 (en) 2001-05-25
AR031680A1 (es) 2003-10-01
NO20022289L (no) 2002-06-24
IS6385A (is) 2002-05-15
KR20020058014A (ko) 2002-07-12
CA2389604A1 (en) 2001-05-25
PT1233964E (pt) 2005-09-30
CO5261607A1 (es) 2003-03-31
NO20022289D0 (no) 2002-05-14
BG106680A (bg) 2003-01-31
CZ20021692A3 (cs) 2003-01-15
DE60020994D1 (de) 2005-07-28
ZA200203316B (en) 2004-02-25
DE60020994T2 (de) 2006-04-27
CN1423651A (zh) 2003-06-11
SK6772002A3 (en) 2002-09-10
MXPA02004911A (es) 2002-09-18
ATE298337T1 (de) 2005-07-15
EE200200251A (et) 2003-06-16
AU1907301A (en) 2001-05-30
EP1233964A1 (en) 2002-08-28
HUP0204245A3 (en) 2004-12-28
ES2242653T3 (es) 2005-11-16
AU784400B2 (en) 2006-03-23
BR0015624A (pt) 2002-07-30
IL149374A0 (en) 2002-11-10
DK1233964T3 (da) 2005-09-19
HUP0204245A2 (hu) 2003-03-28
US6683090B1 (en) 2004-01-27
PL355867A1 (en) 2004-05-31
NZ518571A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
SE9904176D0 (sv) New use
SE9903760D0 (sv) New compounds
TR200102042T2 (tr) Spiro fropiridinlerin, tedavide faydalı yeni aralkil aminleri.
SE9903998D0 (sv) New compounds
GB9801690D0 (en) Therapeutic agents
DE60233239D1 (de) Benzothiazepinderivate
SE0301446D0 (sv) New Compounds
SE9903997D0 (sv) New compounds
ATE346067T1 (de) Carbolinderivate
SE9803518D0 (sv) Novel compounds
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
PT992509E (pt) Novos derivados macrolidos
SE0102055D0 (sv) New Compounds
ATE170852T1 (de) Benzolsulfonamid-derivate zur behandlung der blaseninstabilität
WO2004041802A8 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
SE9803773D0 (sv) Compounds
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
ATE330958T1 (de) Pyrazino 1&#39;2&#39;:1,6öpyrido 3,4-böindolderivate
SE0104326D0 (sv) Therapeutic heterocycles
SE0102057D0 (sv) New Salts I
SE0104333D0 (sv) Therapeutic agents
SE0102058D0 (sv) New Salts II
DE60210981D1 (de) Heteroarylheteroalkylamin derivate und deren verwendung als inhibitoren der stickoxidsynthase
DE60111553D1 (de) Hexahydropyrazino[1&#39;2&#39;:1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
SE0403118D0 (sv) New compounds 2